Close mobile menu×
Close mobile menu

Gulam A. Manji, MD, PhD

Board Certifications: 
Medical Oncology, Internal Medicine
Expertise in: 
Hematology/Oncology, Stomach Cancer, Pancreatic Cancer, Liver Cancer, Colon & Rectal Cancer
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Stomach Cancer
  • Pancreatic Cancer
  • Liver Cancer
  • Hematology/Oncology
  • Colon & Rectal Cancer
  • Sarcoma
  • Pancreatic Tumor
  • Pancreatic Cysts
  • Pancreas Cyst
  • Pancreas Cancer
  • Liver Tumors
  • Liver Masses
  • Liver Lesions
  • Gastrointestinal Malignancy
  • Gastrointestinal Malignancies
  • Gallbladder Cancer
  • Clinical Research Trials

Specialties

Education & Training

  • University of Wisconsin
  • Ross University School of Medicine
  • Residency: Albany Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Gulam Manji

Gulam Manji, M.D., Ph.D. is an Assistant Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology.

Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent.

Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone: (212) 305-5098
Fax:
(212) 305-6762
Primary

Research

Grants

A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFTEY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL (P&S Industry Clinical Trial)

Sep 22 2017 - Sep 22 2022

A PHASE IB/II, OPEN LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY BASED TREATMENT COMBINATINOS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS - PANCREATIC CANCER) (P&S Industry Clinical Trial)

Jun 9 2017 - Jun 9 2022

AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, NOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T-CELLS, ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS (P&S Industry Clinical Trial)

Apr 26 2017 - Apr 26 2022

AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH TEZOLIZUMAB IN PATIENTS WITH LOCALLY (P&S Industry Clinical Trial)

Mar 8 2017 - Mar 8 2022

PHASE 2 STUDY OF COMBINATION THERAPY WITH PLX3397 AND SIROLIMUS TO TARGET TUMOR-ASSOCIATED MACROPHAGES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (Federal Gov)

Mar 5 2017 - Feb 28 2022

A PHASE II STUDY OF CHEMOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE WITH PEMBROLIZUMAB IN THE PERIOPERATIVE AND MAINTENANCE TREATMENT OF LOCOREGIONAL GASTRIC OR GE JUNCTION ADENOCARCINOMA (P&S Industry Clinical Trial)

Jan 12 2017 - Jan 12 2021

A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB AS MONOTHERAPY AND IN COMBINATION WITH CISPLATIN+5-FLUOROURACIL IN SUBJECTS WITH RECURRENT OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (KEYNOTE-059) (P&S Industry Clinical Trial)

Aug 27 2015 - Aug 27 2020

A DOSE ESCALATION AND COHORT EXPANSION STUDY OF DKN-01 IN COMBINATION WITH GEMCITABINE AND CISPLATIN IN PATIENTS WITH ADVANCED CARCINOMA PRIMARY TO THE INTRA- OR EXTRA-HEPATIC BILIARY SYSTEM OR GALLBLADDER (P&S Industry Clinical Trial)

Mar 31 2015 - Mar 31 2020

A PHASE 1B/2 STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB, MEDI4736 MONOTHERAPY, AND TREMELIMUMAB MONOTHERAPY IN SUBJECTS WITH METASTATIC OR RECURRENT GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (P&S Industry Clinical Trial)

Mar 23 2015 - Mar 23 2020

PRECLINICAL EVALUATION OF COMBINATION IMMUNOTHERAPY APPROACHES FOR PANCREATIC DUCTAL ADENOCARCINOMA (Private)

Jul 1 2015 - Jun 30 2016